
Opinion|Videos|June 5, 2024
Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches
Author(s)Ioana Preston, MD
Ioana Preston, MD, highlights treatment considerations for managing PAH in specific patient populations and discusses the unmet needs that can be addressed by novel therapeutic approaches or improved treatment strategies.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- What are the challenges associated with managing pulmonary arterial hypertension (PAH) in specific patient populations, such as those with comorbidities?
- How can the unmet needs in PAH be addressed through the development of novel therapeutic approaches or improved disease management strategies?
Advertisement
Related to this article

Narcolepsy and idiopathic hypersomnia can go undiagnosed for years, and Epworth and RU-SATED screening help clinicians spot true sleepiness sooner.

At CHEST 2026, 3 speakers explained why respiratory medications stay expensive, assessed what recent federal, state, and industry fixes have achieved, and urged clinicians to use their voices on behalf of patients.

Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.

FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.

Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.

Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.

Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Ryzumvi for Presbyopia, Expanding its Label
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
FDA Grants Accelerated Approval to Dostarlimab for dMMR Rectal Cancer
4
AAO 2026: Closing the Screening Gap in Diabetic Retinopathy
5



